Baltabekova et al., 2015 - Google Patents
SplitCore technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgEBaltabekova et al., 2015
View PDF- Document ID
- 1813958223564039807
- Author
- Baltabekova A
- Shagyrova Z
- Kamzina A
- Voykov M
- Zhiyenbay Y
- Ramanculov E
- Shustov A
- Publication year
- Publication venue
- Molecular biotechnology
External Links
Snippet
Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE …
- 238000005516 engineering process 0 title abstract description 9
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
- C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
- C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walker et al. | SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure | |
| Kim et al. | Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles | |
| Jegerlehner et al. | A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses | |
| Denis et al. | Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization | |
| Whitacre et al. | Use of hepadnavirus core proteins as vaccine platforms | |
| Yenkoidiok-Douti et al. | Engineering a virus-like particle as an antigenic platform for a Pfs47-targeted malaria transmission-blocking vaccine | |
| CN103483421B (en) | Polypeptides and antibodies for treating HBV infection and related diseases | |
| Lechner et al. | Virus-like particles as a modular system for novel vaccines | |
| JP5942296B2 (en) | Pharmaceutical composition comprising a polypeptide comprising at least one CXXXC motif and a heterologous antigen, and uses thereof | |
| WO2021147025A1 (en) | Anti 2019-ncov vaccine | |
| Blokhina et al. | A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles | |
| Billaud et al. | Combinatorial approach to hepadnavirus-like particle vaccine design | |
| CN112500456B (en) | Castration AP205 virus-like particle subunit vaccine | |
| JP5138844B2 (en) | Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of antigen and the receptor for EBVGp350 / 220 | |
| EP1268530A1 (en) | Hepatitis b core antigen fusion proteins | |
| Pang et al. | Epitope presentation of dengue viral envelope glycoprotein domain III on hepatitis B core protein virus-like particles produced in Nicotiana benthamiana | |
| JP5160545B2 (en) | Split core particles for presentation of foreign molecules especially applicable to vaccines and methods for their production | |
| Cielens et al. | Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein | |
| JPH09248191A (en) | Fused protein and granule thereof, diagnostic reagent | |
| Baltabekova et al. | SplitCore technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE | |
| Salinas et al. | A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle | |
| CN105777909B (en) | A porcine chemokine-mediated targeting complex epitope protein and vaccine for type A foot-and-mouth disease | |
| WO2018175560A1 (en) | Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain | |
| Guerrero-Rodríguez et al. | Virus-like particles from Escherichia coli-derived untagged papaya ringspot virus capsid protein purified by immobilized metal affinity chromatography enhance the antibody response against a soluble antigen | |
| Manuel-Cabrera et al. | Immune response to a potyvirus with exposed amino groups available for chemical conjugation |